2022 Revenues ($USD) : $45,293,039,800.00
2022 Revenues (foreign currencies) : €42,997,000,000
2022 R&D spend : $7,064,100,400.00
2022 Number of Employees : 91,573
Fiscal Year End : 12/31/22
Leader : CEO Paul Hudson

Sanofi's 2022 performance showcased significant progress in transforming its R&D organization while maintaining strong operational and financial outcomes. The company's specialty care sector, driven by Dupixent, delivered the highest sales among its businesses, reaching €10 billion in 2023. In 2022, the company launched two new molecular entities, Xenpozyme and Enjaymo, and continued to lead in the vaccine market with a focus on pediatric vaccines. Sanofi's 2022 earnings per share grew by 17.1% at constant exchange rates, and its R&D efforts achieved multiple publications in peer-reviewed medical journals. The company is poised for further growth in 2023 with two major launches, ALTUVIIIO for Hemophilia A and Beyfortus for RSV prevention. —BB